Patient case: 70-year-old male with non-small cell lung cancer; genetic feature: KRAS (G12C)

Clinical trial: Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4

Summary: Primary Objective:
  Correlation of the skin and/or eye toxicity grade secondary to Cetuximab or Panitumumab and the SNP profile of the Epidermal Growth Factor Receptor (EGFR) domain III region.
  Secondary Objectives:
  Correlation of SNP profile with indicators of tumour response parameters, such as radiological response, duration of response, time to progression (TTP), overall survival (OS) time, incidence of non-dermatological adverse events.

Detailed description: Baseline assessment:
  -  Contact Lenses
  -  Medical History
  -  Previous chemotherapy
  -  Vital Signs (weight, height, Karnofsky Performance status, heart rate, blood pressure)
  -  Symptom Assessment (Pre-existing skin and/or eye conditions, CEA measurement (CRC only), Disease status (TNM Staging))
  -  Planned chemotherapy regimen
  -  Radiotherapy
  Blood Sample: A 2ml blood sample should be collected in ethylenediamine-tetraacetic acid (EDTA) containing Vacutainer at any time before or after starting treatment. DNA will be extracted from the samples and the 11 SNPs in the region of the EGFR gene encoding domain III will be characterized.
  Follow-up Assessment: with every second cycle of Cetuximab- or Panitumumab-containing regimen (CRC: every 2. Week; NSCLC: every 3-4 weeks):
  -  Visit Number and Date
  -  Vital Signs (weight, height, Karnofsky Performance status, heart rate, blood pressure)
  -  Symptom Assessment (CEA measurement (CRC only), Disease status (TMN Staging), Skin Toxicity (CTCAE) grading)
  -  Current chemotherapy regimen
  -  Radiotherapy
  -  CEA measurement only for CRC (every second cycle/every 4 weeks)
  Long-term follow-up (up to 5 years):
  -  CT restaging (TNM Staging) should be done 3 monthly for as long as the subject is receiving Cetuximab- or Panitumumab- containing regimen or if there is suspicion of disease progression.
  -  OS

Eligibility: Inclusion Criteria:
  1. Stage IV (AJCC 7th Edition TMN Staging, Appendix C), histologically confirmed CRC with wild-type KRAS and not a candidate for metastasectomy.
  2. Stage IV (AJCC 7th Edition, TMN Staging, Appendix C) NSCLC expressing EGFR (IHC tested)
  3. Patients, who will receive treatment with an EGFR-antibody (Cetuximab or Panitumumab).
  4. Karnofsky performance status (Appendix B) score ≥60.
  5. Acceptable laboratory values:
  -  Haemoglobin ≥ 9 g/dL.
  -  Neutrophil count ≥ 1.0 x 10^9/L.
  -  Platelet count ≥100 x 10^9/L.
  -  Serum creatinine ≤1.5 times the upper limit of normal.
  -  Bilirubin ≤1.5 times the upper limit of normal.
  -  Aspartate aminotransferase and alanine aminotransferase ≤5 times the upper limit of normal.
  Exclusion Criteria:
  1. Aged < 18 years
  2. Prior exposure to Cetuximab or Panitumumab
  3. The CRC does not carry wild-type KRAS.
  4. The NSCLC stains negative for EGFR protein expression
  5. Second cancer diagnosis (apart from non-melanoma skin cancer)
  6. Known hypersensitivity to Cetuximab or Panitumumab, or murine protein.
  7. Known history of coronary artery disease, arrhythmias, or congestive heart failure (If the treating physician feels that a patient's coronary artery disease / arrhythmia / congestive heart failure does not place him/her at risk from treatment with an anti-EGFR antibody, the person can be included. This is a clinical decision, which has to be made by the treating physician).
  8. Known to be pregnant (pregnancy test is not mandatory) or breast-feeding.

Relevance to patient case: not relevant